Cargando…

Cyclin B2 (CCNB2) Stimulates the Proliferation of Triple-Negative Breast Cancer (TNBC) Cells In Vitro and In Vivo

Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. Currently, targeting therapy makes great advances for the treatment of TNBC, whereas more effective therapeutic targets are urgently needed. Cyclin B2 (CCNB2), which belongs to B-type cyclins, is known as a cell cycle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Shuai, Su, Rui, Jia, Hongyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331305/ https://www.ncbi.nlm.nih.gov/pubmed/34354775 http://dx.doi.org/10.1155/2021/5511041

Ejemplares similares

Prognostic Significance of CCNB2 Expression in Triple-Negative Breast Cancer
por: Cao, Jintao, et al.
Publicado: (2021)

Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro
por: Choi, Hoon Sik, et al.
Publicado: (2021)

Neural Functions Play Different Roles in Triple Negative Breast Cancer (TNBC) and non-TNBC
por: Tan, Renbo, et al.
Publicado: (2020)

The fate of chemoresistance in triple negative breast cancer (TNBC)
por: O’Reilly, Elma A., et al.
Publicado: (2015)

The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC)
por: Narrandes, Shavira, et al.
Publicado: (2018)

CCNB1 and CCNB2 involvement in the pathogenesis of psoriasis: a bioinformatics study
por: Li, An-hai, et al.
Publicado: (2022)

ISL1, a novel regulator of CCNB1, CCNB2 and c-MYC genes, promotes gastric cancer cell proliferation and tumor growth
por: Shi, Qiong, et al.
Publicado: (2016)

Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
por: Lee, Jieun
Publicado: (2023)

Defining triple‐negative breast cancer with neuroendocrine differentiation (TNBC‐NED)
por: Hacking, Sean M, et al.
Publicado: (2023)

High phosphorylated cyclin-dependent kinase 2 expression indicates poor prognosis of luminal androgen receptor triple-negative breast cancer: pCDK2 in luminal androgen receptor TNBC
por: Jin, Zining, et al.
Publicado: (2022)

Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-β signaling
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2021)

Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy
por: Kim, Sanghwa, et al.
Publicado: (2016)

Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target
por: Koni, Malvina, et al.
Publicado: (2022)

CDK1, CCNB1, and CCNB2 are Prognostic Biomarkers and Correlated with Immune Infiltration in Hepatocellular Carcinoma
por: Zou, Yiping, et al.
Publicado: (2020)

A pancancer analysis of the oncogenic role of cyclin B1 (CCNB1) in human tumors
por: Dai, Peng, et al.
Publicado: (2023)

B4GALNT2 Gene Promotes Proliferation, and Invasiveness and Migration Abilities of Model Triple Negative Breast Cancer (TNBC) Cells by Interacting With HLA-B Protein
por: Yu, Pu, et al.
Publicado: (2021)

Towards an immunoscore for triple negative breast cancer (TNBC): lymphocytic infiltrate predicts outcome
por: Adams, Sylvia, et al.
Publicado: (2013)

Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice
por: Schneeweiss, Andreas, et al.
Publicado: (2019)

Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)
por: Chaudhuri, Aiswarya, et al.
Publicado: (2022)

Tissue Selection for PD-L1 Testing in Triple Negative Breast Cancer (TNBC)
por: Dobritoiu, Florin, et al.
Publicado: (2022)

Differential expression of cyclins CCNB1 and CCNG1 is involved in the chondrocyte damage of kashin-beck disease
por: Setiwalidi, Kaidiriye, et al.
Publicado: (2022)

Recurrent triple-negative breast cancer (TNBC) tissues contain a higher amount of phosphatidylcholine (32:1) than non-recurrent TNBC tissues
por: Hosokawa, Yuko, et al.
Publicado: (2017)

Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
por: Lee, Jung Ok, et al.
Publicado: (2019)

47982 Reversing the resistance to chemotherapy in White and Black patients with triple negative breast cancer (TNBC).
por: Gandhi, Shipra, et al.
Publicado: (2021)

Prognostic Capability of TNBC 3-Gene Score among Triple-Negative Breast Cancer Subtypes
por: Araujo, Jhajaira M., et al.
Publicado: (2022)

Requirement for CCNB1 in mouse spermatogenesis
por: Tang, Ji-Xin, et al.
Publicado: (2017)

Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC)
por: Sheng, Iris Y., et al.
Publicado: (2019)

Predicting Relapse in Patients With Triple Negative Breast Cancer (TNBC) Using a Deep-Learning Approach
por: Yu, Guangyuan, et al.
Publicado: (2020)

Synthesis of Curcumin Derivatives and Analysis of Their Antitumor Effects in Triple Negative Breast Cancer (TNBC) Cell Lines
por: Bonaccorsi, Paola Maria, et al.
Publicado: (2019)

Identification of CXCR4 and CXCL10 as Potential Predictive Biomarkers in Triple Negative Breast Cancer (TNBC)
por: Chuan, Tian, et al.
Publicado: (2020)

Advances in Understanding Mitochondrial MicroRNAs (mitomiRs) on the Pathogenesis of Triple-Negative Breast Cancer (TNBC)
por: Lin, Hung-Yu, et al.
Publicado: (2021)

PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC)
por: Ghosh, Joydeep, et al.
Publicado: (2021)

Spatial Profiling Identifies Prognostic Features of Response to Adjuvant Therapy in Triple Negative Breast Cancer (TNBC)
por: Kulasinghe, Arutha, et al.
Publicado: (2022)

Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy
por: Chaudhuri, Aiswarya, et al.
Publicado: (2022)

Targeting glutamine metabolism enhances responses to platinum-based chemotherapy in triple-negative breast cancers (TNBC)
por: Hong, Jiaxin, et al.
Publicado: (2022)

Effect of miR-205 on proliferation and migration of thyroid cancer cells by targeting CCNB2 and the mechanism
por: Wang, Xin, et al.
Publicado: (2020)

Hsa-mir-3163 and CCNB1 may be potential biomarkers and therapeutic targets for androgen receptor positive triple-negative breast cancer
por: Qiu, Pengjun, et al.
Publicado: (2021)

Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP)
por: Qian, Xiao-Long, et al.
Publicado: (2017)

A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013
por: Ademuyiwa, Foluso O., et al.
Publicado: (2022)

Synergistic antitumor effects of circularly permuted TRAIL with doxorubicin in triple-negative breast cancer: Circularly permuted TRAIL with Dox in TNBC
por: Liu, Jia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_es3gqg2squnp5iu4mjgq0umbs1